Dino Amadori

Summary

Publications

  1. ncbi request reprint Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
    Dino Amadori
    Osteoncology and Rare Tumors Center, IRCCS Scientific Institute of Romagna for the Study and Treatment of Cancer IRST IRCCS, Meldola, Italy
    Lancet Oncol 14:663-70. 2013
  2. doi request reprint Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer
    Chiara Arienti
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Clin Colorectal Cancer 12:122-7. 2013
  3. doi request reprint Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Mol Med 15:316-26. 2011
  4. doi request reprint Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Prostate 70:219-27. 2010
  5. doi request reprint Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 226:3035-42. 2011
  6. doi request reprint Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients
    Toni Ibrahim
    Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Clin Breast Cancer 11:369-75. 2011
  7. doi request reprint A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients
    Dino Amadori
    Romagnolo Scientific Institute for the Study and Treatment of Cancer, Meldola, Italy
    Int J Oncol 42:1778-85. 2013
  8. doi request reprint The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study
    Emanuele Sacanna
    Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Oncology 80:225-31. 2011
  9. doi request reprint Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity
    Anna Tesei
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    J Cell Physiol 227:3389-96. 2012
  10. doi request reprint Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines
    Paola Ulivi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 220:214-21. 2009

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
    Dino Amadori
    Osteoncology and Rare Tumors Center, IRCCS Scientific Institute of Romagna for the Study and Treatment of Cancer IRST IRCCS, Meldola, Italy
    Lancet Oncol 14:663-70. 2013
    ..We assessed the efficacy and safety of a reduced dosing frequency of zoledronic acid in women treated previously with monthly zoledronic acid...
  2. doi request reprint Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer
    Chiara Arienti
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Clin Colorectal Cancer 12:122-7. 2013
    ..In the present study, sensitivity and resistance to drugs used to treat PC were better defined by a conventional chemosensitivity test than by biomarker expression...
  3. doi request reprint Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Mol Med 15:316-26. 2011
    ..Our findings suggest the potential clinical usefulness of treatment with sorafenib and docetaxel for advanced gastric cancer...
  4. doi request reprint Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Prostate 70:219-27. 2010
    ..The aims of the present work were to examine the in vitro activity and mechanisms of action of different antitumor drug combinations in hormone-resistant prostate cancer (HRPC) cell lines...
  5. doi request reprint Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 226:3035-42. 2011
    ..Of note, the activity of NLPDX in taxane-resistant DU145-R cells warrants further evaluation as second-line treatment of advanced HRPC after taxane failure...
  6. doi request reprint Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients
    Toni Ibrahim
    Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Clin Breast Cancer 11:369-75. 2011
    ..CXCR4 expression, alone or in combination with RANK, identified patients destined to relapse to bone...
  7. doi request reprint A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients
    Dino Amadori
    Romagnolo Scientific Institute for the Study and Treatment of Cancer, Meldola, Italy
    Int J Oncol 42:1778-85. 2013
    ..In this study, both combinations showed moderate activity as predefined RR was not reached and were well tolerated...
  8. doi request reprint The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study
    Emanuele Sacanna
    Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Oncology 80:225-31. 2011
    ..The aim of our retrospective case-control study was to evaluate whether CXCR4 expression is more effective than conventional markers (estrogen receptor and HER-2) in predicting bone relapse in breast cancer...
  9. doi request reprint Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity
    Anna Tesei
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    J Cell Physiol 227:3389-96. 2012
    ..Further studies are needed to confirm these preliminary findings...
  10. doi request reprint Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines
    Paola Ulivi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 220:214-21. 2009
    ..Our results show that sorafenib exerts anti-proliferative and pro-apoptotic activity in pancreatic cancer cells. Used singly or in combination with other drugs, it could therefore represent valid treatment for pancreatic cancer...
  11. doi request reprint Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care
    Marco Maltoni
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Support Care Cancer 20:2829-36. 2012
    ..We investigated PS for refractory symptoms in different hospice casemixes in order to (1) assess clinical decision-making, (2) monitor the practice of PS, and (3) examine the impact of PS on survival...
  12. doi request reprint Bone metastases detection by circulating biomarkers: OPG and RANK-L
    Laura Mercatali
    Osteoncology Centre, Istituto Scientifico Romagnolo per Studio e Cura dei Tumori, Meldola, Italy
    Int J Oncol 39:255-61. 2011
    ..For VMP, OPG and RANK-L were expressed in only one patient. Our results highlight the potentially important role of circulating OPG in the diagnosis of bone metastases. A confirmatory study on a larger case series is ongoing...
  13. doi request reprint Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?
    Chiara Molinari
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    J Cell Physiol 228:2343-9. 2013
    ..Conversely, with the exception of TIMP3 gene, the methylation of selected genes does not seem to correlate with response to NCRT...
  14. doi request reprint Biofunctional characteristics of in situ and invasive breast carcinoma
    Sara Bravaccini
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Meldola, FC, Italy
    Cell Oncol (Dordr) 36:303-10. 2013
    ..We also aimed to identify markers in tumor and normal surrounding tissues that may be predictive of locoregional recurrence in patients with DCIS...
  15. doi request reprint Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
    Francesco Fabbri
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Cancer Lett 335:225-31. 2013
    ..Our results present dielectrophoresis-based procedures as a new standard in single cell analysis and recovery and invite careful reflection on the value of CTCs characterization...
  16. pmc Multiple marker detection in peripheral blood for NSCLC diagnosis
    Paola Ulivi
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    PLoS ONE 8:e57401. 2013
    ..We analyzed the diagnostic accuracy of a panel of peripheral blood markers in detecting non small cell lung cancer (NSCLC)...
  17. doi request reprint Metastatic bone disease in the era of bone-targeted therapy: clinical impact
    Toni Ibrahim
    Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Tumori 99:1-9. 2013
    ..We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting...
  18. pmc RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study
    Laura Mercatali
    Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, via P Maroncelli 40, 47014 Meldola FC, Italy
    Int J Mol Sci 14:10683-93. 2013
    ..Median serum NTX levels decreased over the 12-month period, reaching statistical significance (p < 0.0001). Our results would seem to indicate that ZA modulates RANK, RANK-L and OPG expression, thus decreasing osteoclast activity...
  19. ncbi request reprint Palliative sedation in end-of-life care and survival: a systematic review
    Marco Maltoni
    Istituto Scientifico Romagnolo per lo Studio e lCura dei Tumori, Meldola, Italy
    J Clin Oncol 30:1378-83. 2012
    ..We present a systematic review of literature on the clinical practice of palliative sedation to assess the effect, if any, on survival...
  20. doi request reprint Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue
    Paola Ulivi
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, FC, Italy
    J Clin Pathol 66:708-10. 2013
    ....
  21. pmc Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid
    Toni Ibrahim
    Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Via P, Maroncelli 40, 47014, Meldola, FC, Italy
    Cancer Cell Int 12:48. 2012
    ..abstract:..
  22. pmc Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
    Alessandro Passardi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Transl Med 6:65. 2008
    ..The aim of the present study was to evaluate and compare two treatment schedules, one based on our own preclinical data and the other selected from the literature...
  23. doi request reprint Activity of lipoplatin in tumor and in normal cells in vitro
    Chiara Arienti
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, via P Maroncelli 40, Meldola, Italy
    Anticancer Drugs 19:983-90. 2008
    ..Moreover, ERCC1 and LRP expression levels would seem to be valid predictors of sensitivity or resistance to these drugs...
  24. doi request reprint Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer
    Toni Ibrahim
    Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Clin Pharmacol 52:361-9. 2012
    ..These findings have safety implications for poor metabolizers whose drug clearance may fall below the threshold during repeated treatment cycles...
  25. pmc KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)
    Andrea Casadei Gardini
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
    PLoS ONE 9:e92071. 2014
    ..These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC. ..
  26. pmc Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models
    Anna Tesei
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    PLoS ONE 8:e62657. 2013
    ..Our in vitro results highlight the antitumor activity of the two novel molecules (R)-9 and (S)-11, making them a potentially attractive option for the treatment of CRPC...
  27. pmc First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer
    Gianluca Tedaldi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
    BMC Cancer 14:478. 2014
    ..CHEK2 is a multi-cancer susceptibility gene whose common germline mutations are known to contribute to the risk of developing breast and prostate cancer...
  28. pmc Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy
    Chiara Arienti
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    J Transl Med 9:94. 2011
    ....
  29. doi request reprint Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients
    Paola Ulivi
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Int J Oncol 41:147-52. 2012
    ..K-ras mutations were detected in 8 (32%) fresh samples, and in 9 (36%) fixed cytological smears. Fixed and stained cytological samples seem to be more reliable than fresh material for molecular analysis...
  30. doi request reprint Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer
    Dino Amadori
    Cancer Institute of Romagna I R S T, Meldola, Italy
    Breast Cancer Res Treat 125:775-84. 2011
    ..Further molecular characterization of the tumors might help to identify subgroups achieving higher benefit from either sequence...
  31. doi request reprint Ipilimumab in advanced melanoma: reports of long-lasting responses
    Alberto Farolfi
    Immunotherapy and Somatic Cell Therapy Unit bRadiology Unit, Cancer Institute of Romagna, Meldola, FC, Italy
    Melanoma Res 22:263-70. 2012
    ..Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, supporting the need for further irRC validation...
  32. ncbi request reprint Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches
    Sara Bravaccini
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    J Clin Pathol 65:183-5. 2012
    ..In conclusion, MLPA is a fast and accurate quantitative method to detect HER2 and Topo 2 amplification, and could be considered a good alternative to FISH...
  33. pmc Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
    Chiara Molinari
    Biosciences Laboratories, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Radiat Oncol 6:161. 2011
    ..The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies...
  34. pmc FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy
    Giovenzio Genestreti
    1 Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    J Cancer 3:241-5. 2012
    ..In our case series, the metabolic response measured by SUVmean seems to be in better agreement with the radiologic response compared to the SUVmax...
  35. ncbi request reprint GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer
    Carlo Milandri
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    Hepatogastroenterology 58:599-603. 2011
    ..The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer...
  36. ncbi request reprint Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients
    Alberto Farolfi
    Department of Medical Oncology, Oncology Pharmacy Unit, Biostatistics and Clinical Trials Unit, IT Unit, Anesthesiology Unit, Cardiology Unit, and Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
    Oncologist 19:823-8. 2014
    ..The impact of cytotoxic agents on the risk of acute allergy-like adverse reactions (ARs) to intravenous iodinated contrast media (ICM) injections is unknown...
  37. ncbi request reprint Hemangioblastoma of the gastrointestinal tract: a first case
    Andrea Casadei Gardini
    IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Int J Surg Pathol 21:192-6. 2013
    ..Immunohistochemically, the cells showed positivity for inhibin and NSE and weak positivity for S-100. A diagnosis of hemangioblastoma was made. This case highlights that hemangioblastoma of the gastrointestinal tract can also occur...
  38. pmc Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium
    Emanuela Scarpi
    Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Oncologist 16:1793-9. 2011
    ..The PaP score assigns patients to three different risk groups according to a 30-day survival probability--group A, >70%; group B, 30%-70%; group C, <30%. The impact of delirium is known but was not incorporated into the PaP score...
  39. doi request reprint Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G)
    Gerardo Musuraca
    Department of Hematology, Istituto Scientifico Romagnolo per Studio e Cura dei Tumori, Meldola, Italy
    Am J Hematol 86:79-80. 2011
    ..Several novel therapeutic approaches have been proposed for these patients including monoclonal antibodies, radioimmunotherapy, proteasome inhibitors, mTOR inhibitors, and the immunomodulatory drugs such as thalidomide and lenalidomide...
  40. ncbi request reprint Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations
    Ian J Seymour
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC, Italy
    Breast Cancer Res Treat 112:343-9. 2008
    ..This information shows that a correct and accurate clinical selection could avoid unnecessary molecular tests and could better address genetic analysis and clinical management...
  41. ncbi request reprint Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model
    Toni Ibrahim
    Osteo Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Tumori 95:291-7. 2009
    ....
  42. pmc Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    J Transl Med 6:43. 2008
    ..In prostate cancer, the identification of drug combinations that could reduce the tumor cell population and rapidly eradicate hormone-resistant cells potentially present would be a remarkable breakthrough in the treatment of this disease...
  43. doi request reprint Clinical implications of microRNAs in lung cancer
    Francesca Fanini
    Gene Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Semin Oncol 38:776-80. 2011
    ..This review focuses on these translational aspects of research on the field of miRNAs and lung cancer...